Q4 2022 Results
Company overview
Innovation: Pipeline overview
Financial review
Novartis pipeline in Phase 2
Solid Tumors
Code
AAA601
Name
LutatheraⓇ
Mechanism
Indication(s)
Radioligand therapy target SSTR GEPNET, pediatrics
Ad2AR inhibitor, PD1 inhibitor
JDQ443 JDQ443
KRAS inhibitor
NIR178
NIS793 NIS793
TNO155 TNO155
NIR178, spartalizumab
TGFB inhibitor
SHP2 inhibitor
1L ES-SCLC
Glioblastoma
NSCLC (combo)
Cancers
1L metastatic colorectal cancer
Solid tumors (single agent)
2023 priorities
Appendix
Innovation: Clinical trials
Abbreviations
28 lead indications
Lead indication
Hematology
Code
ABL001
Name
ScemblixⓇ
INC424 JakaviⓇ
LNP023 iptacopan
MBG453 sabatolimab
PHE885 PHE885
PKC412 Rydapt
YTB323
rapcabtagene autoleucel
Cardiovascular
Mechanism
BCR-ABL inhibitor
JAK1/2 inhibitor
CFB inhibitor
TIM3 antagonist
BCMA cell therapy
Multi-targeted kinase inhibitor.
CD19 CAR-T
Indication(s)
Chronic myeloid leukemia, 2L, pediatrics
Acute GVHD, pediatrics
Immune thrombocytopenia
Unfit acute myeloid leukemia
Acute myeloid leukemia, maintenance
4L multiple myeloma
Acute myeloid leukemia, pediatrics
1L high-risk large B-cell lymphoma
Chronic GVHD, pediatrics
Code
Hidradenitis suppurativa
Name
CFZ533 iscalimab
HSY244 HSY244
LNP023 iptacopan
MBL949 MBL949
TIN816 TIN816
XXB750 XXB750
Mechanism
CD40 inhibitor
CFB inhibitor
ATP modulator
Immunology
Code
Name
CFZ533
iscalimab
CMK389 CMK389
DFV890 DFV890
Mechanism
CD40 inhibitor
IL-18 inhibitor
NLRP3 inhibitor
LNA043 LNA043
ANGPTL3 agonist
LOU064
remibrutinib
BTK inhibitor
Indication(s)
Sjögren's
Atopic dermatitis
Osteoarthritis
Familial cold auto-inflammatory syndrome
Knee osteoarthritis
Osteoarthritis (combos)
Food allergy
Hidradenitis suppurativa
Sjögren's
Others
NPR1 agonist
Indication(s)
Lupus nephritis Type 1 diabetes mellitus
Atrial fibrillation
Lupus nephritis
Obesity related diseases
Acute kidney injury
Hypertension
LRX712 LRX712
LYS006 LYS006
MAS825 MAS825
MHV370 MHV370
QUC398 QUC398
VAY736 ianalumab
Neuroscience
Code
Anti-inflammatory
Osteoarthritis
Colitis ulcerative
Hidradenitis suppurativa
NLRC4-GOF indications
Sjögren's
Mixed connective tissue disease
Osteoarthritis
Autoimmune hepatitis
ADAMTS5 inhibitor
BAFF-R inhibitor
Systemic lupus erythematosus
Mechanism
Name
ADPT06 ADPT06
BLZ945 sotuletinib
CSF-1R inhibitor
DLX313
MIJ821
DLX313 (UCB0599)
onfasprodil
1. Gyroscope acquisition.
Alpha-synuclein Inhibitor
NR2B negative allosteric
modulator
Indication(s)
Cognitive impairment
Amyotrophic lateral sclerosis
Parkinson's disease
Major depressive disorder with acute suicidal ideation or behavior
Code
Name
Global Health
KAE609
cipargamin
KAF156 ganaplacide
LXE408 LXE408
QMF149 Atectura®
SEG101 Adakveo®
SKO136 ensovibep
Respiratory & Allergy
CMK389 CMK389
LTP001
Ophthalmology
LKA651 LKA651
LNP023 iptacopan
PPY9881 PPY988
PfATP4 inhibitor
Non-artemisinin plasmodium
falciparum inhibitor
Proteasome inhibitor
Combo
P-selectin inhibitor
Multi-specific DARPin
IL-18 inhibitor
SMURF1 inhibitor
EPO inhibitor
CFB inhibitor
Gene therapy - Complement
factor I modulation
Mechanism
Malaria, severe
Malaria, uncomplicated
Visceral leishmaniasis
Asthma, pediatrics
Sickle cell disease, pediatrics
Corona virus infection
Pulmonary sarcoidosis
Pulmonary arterial hypertension
Idiopathic pulmonary fibrosis
Diabetic eye disease
¡AMD
Geographic atrophy
54 Investor Relations | Q4 2022 Results
Indication(s)
Malaria, uncomplicated
U NOVARTIS | Reimagining MedicineView entire presentation